Necat Yılmaz, Esin Eren, Seçkin Özgür Tekeli, Feyza Yağmur Tekeli

Association between serum gamma-glutamyltransferaselevels and hyperuricemia

Aim: Although the the contribution of gamma-glutamyltransferase (GGT) to hyperuricemia (hUA) has been previously shown inliterature, there is not any study showing the contribution of GGT to hUA in a Turkish population. The aim of this study was toinvestigate both the association between GGT and uric acid (UA) and the contribution of GGT to hUA in the Turkish population. Materials and Methods: This retrospective study was conducted in Antalya, Turkey. A total of 14049 subjects (5521 males and 8528females) aged > 40 years were recruited and divided into four subgroups according to serum GGT quartiles. Patient demographicdata and laboratory results of biochemical parameters were obtained from electronic medical records. Linear regression analysiswas applied to GGT quartiles with UA and binary logistic regression analysis was applied to GGT quartiles with hUA. Results: Firstly, serum UA levels were increased across GGT quartiles (p < 0.001). Linear regression models showed GGT in thefourth quartile was strong associated with a 0.22 mmol/L (95% confidence interval (CI) 0.16- 0.29, p = 0.001) increase in UA afteradjustment. Logistic regression analysis revealed that compared with subjects in the lowest GGT quartile, the adjusted oddsratio (OR) for hyperuricemia in the fourth quartile was 2.62 (95% CI 2.27- 3.01, p = 0.001) after adjustment for age, sex, creatinine,total cholesterol (TC), high density lipoprotein (HDL) cholesterol, triglyceride (TG), glycosylated hemoglobin (HbA1c) and alanineaminotransferase (ALT). Conclusions: Serum GGT is closely associated with serum UA and might contributes greatly to hUA.

PDF

___

1. Lee DH, Jacobs DR Jr, Gross M, et al. Gammaglutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 2003;49:1358-66.
2. Nakanishi N, Suzuki K, Tatara K. Serum gammaglutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004;27:1427-32.
3. Kazemi-Shirazi L, Endler G, Winkler S, et al. Gamma glutamyltransferase and long-term survival: is it just the liver? Clin Chem 2007;53:940-6.
4. Ruttmann E, Brant LJ, Concin H, et al. Vorarlberg Health Monitoring and Promotion Program Study Group. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005;112:2130-7.
5. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-21.
6. Nakamura K, Sakurai M, Miura K, et al. Serum gammaglutamyltransferase and the risk of hyperuricemia: a 6-year prospective study in Japanese men. Horm Metab Res 2012;44:966-74.
7. Zhang JX, Xiang GD, Xiang L, et al. Serum gammaglutamyl transferase is associated with the elevated uric acid levels in normotensive Chinese adults. Clin Chim Acta 2015;44:122-6.
8. Ya Z, Fei L, Yue Z, et al. Association between serum gamma-glutamyl transferase and serum uric acid levels in Chinese females: A cross-sectional study. Endocr Res 2017;42:296-301.
9. Onat A, Can G, Ornek E, et al. Elevated serum uric acid in nondiabetic people mark pro-inflammatory state and HDL dysfunction and independently predicts coronary disease. Clin Rheumatol 2013;32:1767-75.
10. Shaw LM, Strømme JH, London JL, et al. International Federation of Clinical Chemistry, (IFCC), Scientific Committee, Analytical Section. IFCC methods for the measurement of catalytic concentration of enzymes. Part 4. IFCC method for gamma-glutamyltransferase [(gamma-glutamyl)-peptide: amino acid gammaglutamyltransferase, EC 2.3.2.2]. J Clin Chem Clin Biochem 1983;21:633-46.
11. Fossati P, Prencipe L, Berti G. Use of 3,5-dichloro-2- hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. Clin Chem 1980;26:227-31.
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
13. Afzali A, Weiss NS, Boyko EJ, et al. Association between serum uric acid level and chronic liver disease in the United States. Hepatology 2010;52:578-89.
14. Nilssen O, Førde OH, Brenn T. The Tromsø Study. Distribution and population determinants of gammaglutamyltransferase. Am J Epidemiol 1990;132:318- 26.
15. Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007;27:127-33.
16. Li M, Hou W, Zhang X, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies. Atherosclerosis 2014;232:265- 70.
17. Krishnan E, Baker JF, Furst DE, et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54:2688-96.
18. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894-900.
19. Nannipieri M, Gonzales C, Baldi S, et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 2005;28:1757-62.
20. Wang T, Bi Y, Xu M, et al. Serum uric acid associates with the incidence of type 2 diabetes in a prospective cohort of middle-aged and elderly Chinese. Endocrine 2011;40:109-16.
21. Franzini M, Corti A, Martinelli B, et al. Gammaglutamyltransferase activity in human atherosclerotic plaques--biochemical similarities with the circulating enzyme. Atherosclerosis 2009;202:119-27.
22. Wannamethee SG, Lennon L, Shaper AG. The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis 2008;201:168- 75.
23. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
24. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35:367-72.
25. Yu MA, Sánchez-Lozada LG, Johnson RJ, et al. Oxidative stress with an activation of the reninangiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 2010;28:1234- 42.
26. Erdogan D, Gullu H, Caliskan M, et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract 2005;59:1276-82.
27. Tsouli SG, Liberopoulos EN, Mikhailidis DP, et al. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006;55:1293-301.
28. Quiñones Galvan A, Natali A, Baldi S, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol 1995;268:1-5.
29. Leyva F, Wingrove CS, Godsland IF, et al. The glycolytic pathway to coronary heart disease: a hypothesis. Metabolism 1998;47:657-62.
30. Modan M, Halkin H, Karasik A, et al. Elevated serum uric acid--a facet of hyperinsulinaemia. Diabetologia 1987;30:713-8.
31. Kozan O, Oguz A, Abaci A, et al. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr 2007;61:548-53